Evidence map›Paper›PMID 40386907›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2025

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

Iqtidar Hanif, Shervin Assassi, Maureen D Mayes, Zsuzsanna H McMahan, Meng Zhang, Julio Charles, John M VanBuren, Jessica S Alvey, Kimia Ghaffari, Elana J Bernstein and 23 more

Abstract readComparative Study
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Iqtidar HanifUniversity of Texas Health Science Center at Houston.
Shervin AssassiUniversity of Texas Health Science Center at Houston.ORCID https://orcid.org/0000-0002-8059-9978
Maureen D MayesUniversity of Texas Health Science Center at Houston.ORCID https://orcid.org/0000-0001-5070-2535
Zsuzsanna H McMahanUniversity of Texas Health Science Center at Houston.ORCID https://orcid.org/0000-0001-6461-8940
Meng ZhangUniversity of Texas Health Science Center at Houston.
Julio CharlesUniversity of Texas Health Science Center at Houston.
John M VanBurenUniversity of Utah, Salt Lake City.
Jessica S AlveyUniversity of Utah, Salt Lake City.
Kimia GhaffariUniversity of Utah, Salt Lake City.
Elana J BernsteinColumbia University Irving Medical Center, New York City, New York.
Flavia V CastelinoMassachusetts General Hospital, Boston.ORCID https://orcid.org/0000-0001-9862-0299
Lorinda ChungPalo Alto VA Health Care System and Stanford University, Palo Alto, California.
Luke EvninScleroderma Research Foundation, San Francisco, California.
Tracy M FrechVanderbilt University Medical Center and Veterans Affairs Medical Center, VA Tennessee Valley Healthcare System, Nashville.ORCID https://orcid.org/0000-0002-5472-3840
Jessica K GordonHospital for Special Surgery, New York City, New York.ORCID https://orcid.org/0000-0001-8068-0592
Faye N HantMedical University of South Carolina, Charleston.
Laura K HummersJohns Hopkins University, Baltimore, Maryland.ORCID https://orcid.org/0000-0002-4864-4011
Dinesh KhannaUniversity of Michigan, Ann Arbor.ORCID https://orcid.org/0000-0003-1412-4453
Kimberly S LakinHospital for Special Surgery, New York City, New York.
Dorota Lebiedz-OdrobinaUniversity of Utah, Salt Lake City.
Yiming LuoColumbia University Irving Medical Center, New York City, New York.
Ashima MakolMayo Clinic, Rochester, Minnesota.
Jerry A MolitorUniversity of Minnesota, Minneapolis.
Duncan F MooreNorthwestern University, Chicago, Illinois.
Carrie RichardsonNorthwestern University, Chicago, Illinois.
Nora SandorfiUniversity of Pennsylvania, Philadelphia.
Ami A ShahJohns Hopkins University, Baltimore, Maryland.
Ankoor ShahDuke University, Durham, North Carolina.
Victoria K ShanmugamThe George Washington University, Washington, DC.ORCID https://orcid.org/0000-0002-5882-4884
Virginia D SteenGeorgetown University Medical Center, Washington, DC.
Elizabeth R VolkmannUniversity of California, Los Angeles.ORCID https://orcid.org/0000-0003-3750-6569
Carleigh ZahnUniversity of Michigan, Ann Arbor.ORCID https://orcid.org/0009-0005-9683-6973
Brian SkaugUniversity of Texas Health Science Center at Houston.ORCID https://orcid.org/0000-0002-6689-4655

Funding

CTSA UM1 Program at University of UtahUM1TR004409 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI RACHEL HESS, Jennifer Juhl Majersik · 2023 to 2026
$21.9M
Vasculopathy and Systemic Sclerosis-Associated Interstitial Lung DiseaseR01HL164758 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Elana J. Bernstein · 2022 to 2026
$3.5M
Interferon Regulatory Factor 7 Links Interferon Pathway Activation to the Exaggerates Fibrotic Response in Systemic SclerosisR01AR081280 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Shervin Assassi, Minghua Wu · 2023 to 2026
$1.1M
Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in sclerodermaK24AR080217 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI Ami Aalok Shah · 2022 to 2026
$847k
Pathogenic effects of the DNASE1L3 R206C variant in systemic sclerosisK08AR081402 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Brian Skaug · 2022 to 2026
$821k
Screening Chest CT to Detect Interstitial Lung Disease in Systemic SclerosisK23AR075112 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERNSTEIN, ELANA · 2019 to 2023
$794k
NCATS NIH HHS UM1 TR004409NHLBI NIH HHS R01 HL164758NIAMS NIH HHS K08 AR081402NIAMS NIH HHS K08AR081402NIAMS NIH HHS K23 AR075112NIAMS NIH HHS K23AR075112NIAMS NIH HHS K24 AR080217NIAMS NIH HHS R01 AR081280NIAMS NIH HHS R01AR081280NIAMS NIH HHS RO1HL164758Rheumatology Research FoundationScleroderma Research FoundationU.S. Department of Defense DOD-W81XWH-22-1-0162U.S. Department of Defense DOD-W81XWH-22-1-0163
6 · The paper itself

Abstract

objectiveRaynaud phenomenon (RP) is often the initial clinical manifestation of systemic sclerosis (SSc), but some patients develop other manifestations first. To help elucidate the diversity of SSc presentation in its early stages, we describe the initial clinical manifestations and antinuclear antibody (ANA) profiles of patients in two early SSc cohorts.

methodsAll patient data in the Genetics vs Environment in Scleroderma Outcomes Study (GENISOS) and Collaborative National Quality and Efficacy Registry (CONQUER) cohorts were reviewed. Both studies enrolled patients within five years of the first non-RP symptom.

resultsIn GENISOS and CONQUER, respectively, 194 (44.2%) of 439 and 292 (31.1%) of 938 patients had a non-RP initial symptom, most commonly puffy fingers/hands. Black patients had a non-RP symptom before RP more commonly than patients in other race and ethnicity categories. Non-RP first patients were more likely than RP first patients to have diffuse cutaneous involvement and joint contractures at enrollment and had a higher prevalence of RNA polymerase III antibody positivity.

conclusionIn two large US cohorts, >30% of patients began to manifest SSc with puffy fingers/hands or other symptoms, without the "warning sign" of RP as their initial symptom. These patients presented with more severe skin and musculoskeletal disease on average, highlighting the importance of early recognition. The most common autoantibody associated with this presentation was RNA polymerase III. These results should be considered in efforts to recognize SSc in its earliest stages. Puffy fingers/hands, even in the absence of RP, should prompt consideration of early SSc and testing for ANA and SSc-associated autoantibodies, including RNA polymerase III.

Indexed as

EdemaHandRaynaud DiseaseScleroderma, SystemicAdultAgedAntibodies, AntinuclearBlack or African AmericanCohort StudiesContractureFemaleHumansMaleMiddle AgedPrevalenceRNA Polymerase IIIAntibodies, AntinuclearRNA Polymerase III

Identifiers

PMID40386907
PMCPMC12353935

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.